ACAD
Acadia Pharmaceuticals
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: ACAD
- PE Ratio
The P/E ratio for Acadia Pharmaceuticals stock stands at 11.65 as of Jul 2, 2026. The calculation is based on the latest EPS of $2.23 and the stock price of $25.97 per share. A decrease of 9% has been observed in the PE ratio compared to its average of 12.8 of the past four quarters.
ACAD PE ratio history
Over the last two years, the average PE ratio of Acadia Pharmaceuticals has been 23.33. The current 11.65 price-to-earnings ratio is 50% less than the historical average. Analyzing the last two years, ACAD's PE ratio reached its highest point in the Jun 2024 quarter at 90.28, with a price of $16.25 and an EPS of $0.18. The Mar 2026 quarter saw the lowest point at 9.98, with a price of $22.26 and an EPS of $2.23.
Acadia Pharmaceuticals PE ratio by year
Maximum annual decrease: -14.04% in 2025
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 11.51 | -14.04% | $26.71 | $2.32 |
| 2024 | 13.39 | N/A | $18.35 | $1.37 |
| 2023 | N/A | N/A | $31.31 | -$0.37 |
| 2022 | N/A | N/A | $15.92 | -$1.34 |
| 2021 | N/A | N/A | $23.34 | -$1.05 |
| 2020 | N/A | N/A | $53.46 | -$1.79 |
| 2019 | N/A | N/A | $42.78 | -$1.6 |
| 2018 | N/A | N/A | $16.17 | -$1.94 |
| 2017 | N/A | N/A | $30.11 | -$2.36 |
| 2016 | N/A | N/A | $28.84 | -$2.34 |
| 2015 | N/A | N/A | $35.65 | -$1.63 |
| 2014 | N/A | N/A | $31.75 | -$0.95 |
| 2013 | N/A | N/A | $24.99 | -$0.44 |
| 2012 | N/A | N/A | $4.65 | -$0.38 |
| 2011 | N/A | N/A | $1.08 | -$0.44 |
Acadia Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 9.98 | -13.29% | $22.26 | $2.23 |
| Dec 2025 | 11.51 | -15.31% | $26.71 | $2.32 |
| Sep 2025 | 13.59 | -15.59% | $21.34 | $1.57 |
| Jun 2025 | 16.1 | 33.72% | $21.57 | $1.34 |
| Mar 2025 | 12.04 | -10.08% | $16.61 | $1.38 |
| Dec 2024 | 13.39 | -32.1% | $18.35 | $1.37 |
| Sep 2024 | 19.72 | -78.16% | $15.38 | $0.78 |
| Jun 2024 | 90.28 | N/A | $16.25 | $0.18 |
| Mar 2024 | N/A | N/A | $18.49 | -$0.01 |
| Dec 2023 | N/A | N/A | $31.31 | -$0.37 |
| Sep 2023 | N/A | N/A | $20.84 | -$0.92 |
| Jun 2023 | N/A | N/A | $23.95 | -$0.69 |
| Mar 2023 | N/A | N/A | $18.82 | -$0.91 |
| Dec 2022 | N/A | N/A | $15.92 | -$1.34 |
| Sep 2022 | N/A | N/A | $16.36 | -$1.35 |
ACAD Price vs fair value
ACAD average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, ACAD's PE ratio is under its 3, 5 and 10-year averages.
PE comparison
Acadia Pharmaceuticals's price to earnings (P/E) of 11.65 is lower than the Healthcare sector, the industry and its peers average. Looking at the Healthcare sector average of 26.04, Acadia Pharmaceuticals's price to earnings (P/E) is 55% lower.
ACAD PE vs peers
When compared to its peer stocks LLY and JNJ, ACAD's PE ratio is lower. Acadia Pharmaceuticals is currently trading at a lower PE ratio (11.65) than its peers average of 27.01.
| Stock name | PE ratio | Market cap |
|---|---|---|
| ACAD Acadia Pharmaceuticals Inc | 11.65 | $4.45B |
| BMY Bristol Myers Squibb Co | 16.28 | $118.71B |
| PFE Pfizer Inc | 18.56 | $138.61B |
| JNJ Johnson & Johnson | 30.13 | $633.19B |
| LLY ELI LILLY & Co | 43.06 | $1.14T |
| VNDA Vanda Pharmaceuticals Inc | N/A | $373.44M |
Frequently asked questions
What is Acadia Pharmaceuticals's PE ratio?
The price to earnings ratio for ACAD stock as of Jul 2, 2026, stands at 11.65.
What is the 3-year average PE ratio for Acadia Pharmaceuticals (ACAD)?
As an average over the last 3 years, ACAD stock has a PE ratio of 23.33.
What is the 5-year average PE ratio for Acadia Pharmaceuticals (ACAD)?
As an average over the last 5 years, ACAD stock has a PE ratio of 23.33.
What is the highest PE ratio for ACAD?
The highest quarterly PE ratio in the last two years has been 90.28 and it was in the Jun 2024 quarter.
How does the current PE ratio for ACAD compare to its historical average?
ACAD's current price to earnings ratio is 50% below its 2-year historical average.
How is ACAD's PE ratio calculated (Acadia Pharmaceuticals PE ratio formula)?
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jul 2, 2026), Acadia Pharmaceuticals's share price is $25.97. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $2.23. Therefore, Acadia Pharmaceuticals's price to earnings ratio for today is 11.65. PE RATIO(11.65) = STOCK PRICE($25.97) / TTM EPS($2.23)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.